Skip to main content

Eli Lilly and Company(LLY-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low975.51
Day High998.17
Open:991.98
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Eli Lilly and Company

Select a category then submit the form to load news
the globe and mail
Fiona Wilson, senior portfolio manager with i3 Investments at Guardian Capital LP in Toronto. Illustration by Joel Kimmel
the globe and mail

Why this $6.3-billion money manager is buying Eli Lilly and selling a software firm

Fiona Wilson at Guardian Capital LP in Toronto also likes semiconductor company ASML
Motley Fool
Should You Avoid Pfizer? Here's the Key Risk to Watch
Motley Fool
Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price?
Motley Fool
Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks
StockStory
3 Quality Compounders to Own for Decades
VRT
Motley Fool
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares
Motley Fool
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share
MarketBeat
3 Stocks That Could Be Next to Announce a Stock Split
MarketBeat.com
MarketBeat
Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand
MarketBeat.com
Tipranks
Lilly Advances Eloralintide Study in High-Risk Kidney Patients: What Investors Should Know
Tipranks
Eli Lilly & Co (LLY) Receives a Buy from Bernstein
Motley Fool
Is Eli Lilly's Weight Loss Empire in Trouble?
MarketBeat
The Real Reason Eli Lilly Is Pouring $3 Billion Into China
MarketBeat.com
Stock Target Advisor
Oil Sinks Stocks as Macro Outlook Dims: Market Analysis for March 12th, 2026
Oil Sinks Stocks as Macro Outlook Dims: Market Analysis for March 12th, 2026
Tipranks
Eli Lilly Advances New LY3985863 Program With Completion of Phase 1 Study in China
Tipranks
Midday Fly By: IEA to release 400M oil barrels, Oracle reports Q3 beat
Motley Fool
Does This Deal Make Novo Nordisk Stock a Buy?
MarketBeat
Megatrends Still Matter: 3 Growth Stocks for the Next 10 Years
MarketBeat.com
Motley Fool
Forget Oral Wegovy: This Weight Loss Drug Could Be an Even Bigger Winner
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Elanco Animal Health (ELAN), Eli Lilly & Co (LLY)
Motley Fool
Asset Manager Exits Shares of Hims & Hers Health
Newswire.ca
BMO Hosts Third Annual Metabolic Health Summit on the Future of the GLP-1+ Market
Tipranks
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Ardent Health Partners, Inc. (ARDT) and Caribou Biosciences (CRBU)
Motley Fool
Should You Buy Eli Lilly Stock Now or Wait for More of a Pullback?
Motley Fool
Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stock
Motley Fool
2 Top AI Healthcare Stocks to Buy and Hold
Zacks Investment Research
Zacks Market Edge Highlights: Caterpillar, Eli Lilly and Comfort Systems
Zacks Market Edge Highlights: Caterpillar, Eli Lilly and Comfort Systems
Motley Fool
1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid
Motley Fool
2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $1,000
Motley Fool
2 Underrated Weight Loss Stocks to Buy Now
Motley Fool
Where Will Eli Lilly Stock Be in 10 Years?
Motley Fool
Can This Next-Gen Obesity Drug Save Novo Nordisk?
Motley Fool
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?

Profile

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.